Marksans Pharma Limited

BSE: 524404 NSE: MARKSANS
Marksans Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24110MH1992PLC066364 Incorporated 16 April 1992 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: MARKSANS · BSE: 524404 Public Limited Company pharma
Data last updated
Market Cap
₹15,290 Cr
MARKSANS · NSE
Share Price
₹336.95
-0.13% today
Revenue
₹2,951 Cr
FY 2025-26 · +12.4% YoY
EBITDA
₹601 Cr
Margin 20.4%
Net Profit
₹416 Cr
FY 2025-26 · +9.7% YoY
P/E (TTM)
30.5x
P/B 5.2x
ROE
15.3%
ROCE 19.0%
Debt / Equity
0.12
Interest cover 4.8x

About Marksans Pharma Limited

Data last updated: 26 September 2026

Marksans Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 April 1992, the company has been in operation for over 34 years.

Registered with ROC Mumbai under CIN L24110MH1992PLC066364. Listed on BSE: 524404 and NSE: MARKSANS.

Capital: an authorised share capital of ₹69 Cr and a paid-up capital of ₹45.32 Cr. Formerly known as Tasc Pharmaceuticals Limited and Tasc Industries (India) Limited. It is led by directors including Sandra Saldanha and Varddhman Vikramaditya Jain.

Last AGM: 08 August 2025. Financial statements filed for year ended 31 March 2025. Office: 11Th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri (W), Mumbai, Maharashtra, India – 400053.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,950.94 Cr, a growth of 12.51% compared to the previous year. The net worth stands at ₹3,023.16 Cr (up 22.55% YoY). Total assets are valued at ₹3,401.97 Cr (up 20.76% YoY).

The company has a workforce of approximately 95 employees as per the latest available data.

The company is associated with 1 brand - Marksans Pharma. As per MCA filings, the company has open charges of ₹226 Cr and satisfied charges of ₹337.16 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website marksanspharma.com.

Company Details of Marksans Pharma Limited
CIN L24110MH1992PLC066364
Registration Number 066364
Incorporation Date 16 April 1992
ROC Mumbai
Listing Status Listed (BSE: 524404, NSE: MARKSANS)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Mark Saldanha Managing Director Sandra Saldanha Whole-Time Director Varddhman Vikramaditya Jain Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    marksanspharma.com
  • Social Media
  • Registered Address
    11Th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri (W), Mumbai, Maharashtra, India – 400053
  • Industry
    Pharma, Drug Formulation & Development
Company report
Marksans Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Marksans Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Marksans Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Marksans Pharma Limited

Marksans Pharma Limited has undergone 2 name changes throughout its history. The company was previously known as Tasc Pharmaceuticals Limited, and Tasc Industries (India) Limited. The current legal name is Marksans Pharma Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Marksans Pharma Limited Current
Tasc Pharmaceuticals Limited Previous
Tasc Industries (India) Limited Previous

Associated Brands with Marksans Pharma Limited

Marksans Pharma Limited operates one associated brand: Marksans Pharma. These brands represent Marksans Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Marksans Pharma
Pharmaceutical drug formulations are manufactured, developed, and marketed. marksanspharma.com

Business Activity of Marksans Pharma Limited

Marksans Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Marksans Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Marksans Pharma Limited

Marksans Pharma Limited is audited by M S K A & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
M S K A & Associates Locked Locked Locked
Premium access

Complete auditor history for Marksans Pharma Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Marksans Pharma Limited

Marksans Pharma Limited is currently managed by 8 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Sandra Saldanha Whole-Time Director 25 Sep 2014 12 Years 0 Months Current
Varddhman Vikramaditya Jain Whole-Time Director 24 Jan 2019 7 Years 8 Months Current
Abhinna Mohanty Sundar
Also directs: Rytus Healthcare Private Limited, Ssb Seva Kartavya Private Limited
Director 11 Jul 2019 7 Years 2 Months Current
Mark Saldanha Managing Director 06 Oct 2015 10 Years 11 Months Current
Digant Mahesh Parikh
Also directs: Rossell India Limited, Rossell Techsys Limited, Akansha Consultancy Services Limited
Director 14 Mar 2018 8 Years 6 Months Current
Sunny Sharma
Also directs: Advanced Enzyme Technologies Limited, Arcatron Mobility Private Limited, Lattice Medtech Private Limited and 5 more
Director 11 Aug 2021 5 Years 1 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Marksans Pharma Limited FY 2025-26 filings available

Marksans Pharma Limited reported revenue of ₹2,950.94 Cr (up 12.51% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,951 Cr
+12.5% YoY
EBITDA
₹601 Cr
+12.8% YoY
Profit After Tax
₹416 Cr
+9.7% YoY
Net Worth
₹3,023 Cr
+22.5% YoY
Total Assets
₹3,402 Cr
+20.8% YoY
Total Debt
₹343 Cr
+6.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,9512,6232,1771,8521,4911,3761,134
Revenue growth+12.4%+21.6%+13.6%+22.8%+18.9%+10.0%+8.5%
EBITDA601533459339259340192
EBITDA margin+20.4%+20.3%+21.1%+18.3%+17.4%+24.7%+17.0%
Profit before tax561504424338248302157
Net profit416380314267185236121
Net profit margin+14.1%+14.5%+14.4%+14.4%+12.4%+17.1%+10.6%
EPS (₹)9.228.406.925.884.515.762.95
Balance sheet
Total assets3,4022,8172,3351,8911,336947685
Net worth3,0232,4672,0651,7451,202886636
Total debt34332224412311134.1029.65
Cash & bank99070467471534921293.73
Net working capital2,2691,7851,5001,391914628387
Cash flow
Cash from operations45820723023799.26179233
Cash from investing(249)(49.01)(141)(259)(84.39)(44.85)(59.58)
Cash from financing(70.93)(65.15)(68.73)19879.51(15.29)(114)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue841856754720620708682642
Revenue growth (YoY)+35.6%+20.8%+10.6%+12.2%+5.0%+26.5%+16.3%+20.8%
Other income25.4035.1720.1421.575.6415.3427.85(0.07)
EBITDA213195161144100127139147
EBITDA margin+25.3%+22.8%+21.3%+20.1%+16.1%+17.9%+20.4%+22.9%
Depreciation24.8624.2924.3326.9223.1022.7420.6919.51
Interest7.006.315.945.826.073.442.672.63
Profit before tax20720015113376.59116143125
Tax47.1650.9736.9434.2018.4025.3738.1926.84
Net profit15914911499.1258.1990.7310597.76
EPS (₹)3.473.272.502.171.292.002.312.13
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3411,174853655658600433
Revenue growth+5.3%+35.5%+26.6%+3.4%+12.1%+34.2%+0.3%
EBITDA32420814091.9011411471.50
EBITDA margin+24.1%+17.7%+16.4%+14.0%+17.3%+19.0%+16.5%
Profit before tax39224317213213412452.74
Net profit29918713410310498.3737.88
Net profit margin+22.3%+16.0%+15.7%+15.7%+15.8%+16.4%+8.7%
EPS (₹)6.644.152.952.272.542.400.93
Balance sheet
Total assets1,6701,4001,2351,122801621523
Net worth1,6521,3831,2231,111785600506
Total debt12.1310.848.137.6914.3114.3710.81
Cash & bank4472693124402241063.35
Net working capital1,002738649699434260178
Cash flow
Cash from operations21131.0234.0551.7355.97107108
Cash from investing(141)17.24(114)(195)(128)8.87(24.15)
Cash from financing(39.23)(29.92)(26.22)21070.86(13.53)(81.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue321362340320320299312309
Revenue growth (YoY)+0.5%+20.8%+8.9%+3.8%+25.6%+32.9%+29.2%+50.8%
Other income17.4727.4815.8658.192.016.6422.5120.23
Total expenses239256264248250248252245
EBITDA82.1110675.4572.0770.0551.7659.9463.41
EBITDA margin+25.6%+29.3%+22.2%+22.5%+21.9%+17.3%+19.2%+20.5%
Depreciation8.788.768.838.468.198.187.427.02
Interest0.340.350.360.320.300.310.300.28
Profit before tax90.4612482.1212163.5749.9174.7376.34
Tax21.4232.4421.2121.6915.5212.3119.2613.13

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue841856754720620708682642
Revenue growth (YoY)+35.6%+20.8%+10.6%+12.2%+5.0%+26.5%+16.3%+20.8%
Other income25.4035.1720.1421.575.6415.3427.85(0.07)
EBITDA213195161144100127139147
EBITDA margin+25.3%+22.8%+21.3%+20.1%+16.1%+17.9%+20.4%+22.9%
Depreciation24.8624.2924.3326.9223.1022.7420.6919.51
Interest7.006.315.945.826.073.442.672.63
Profit before tax20720015113376.59116143125
Tax47.1650.9736.9434.2018.4025.3738.1926.84
Net profit15914911499.1258.1990.7310597.76
EPS (₹)3.473.272.502.171.292.002.312.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,9512,6232,1771,8521,4911,3761,134
Revenue growth+12.4%+21.6%+13.6%+22.8%+18.9%+10.0%+8.5%
Other income82.5366.3350.4259.3141.856.690.33
Total expenses2,3502,0901,7191,5131,2321,037942
Employee cost421350294239220197168
EBITDA601533459339259340192
EBITDA margin+20.4%+20.3%+21.1%+18.3%+17.4%+24.7%+17.0%
Depreciation98.6383.3974.2751.8544.7836.1526.66
Interest24.1311.6611.209.138.457.998.75
Profit before tax561504424338248302157
Tax14012110972.3360.7063.6236.42
Net profit416380314267185236121
Net profit margin+14.1%+14.5%+14.4%+14.4%+12.4%+17.1%+10.6%
EPS (₹)9.228.406.925.884.515.762.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3245.3245.3245.3240.9340.9340.93
Reserves & surplus2,9782,4222,0201,7001,068846595
Shareholders' funds (net worth)3,0232,4672,0651,7451,202886636
Minority interest29.5222.4720.8519.9120.7018.8613.11
Secured loans29.5923.0929.0941.5941.2918.7418.89
Unsecured loans31429921581.3669.4915.3610.76
Total debt34332224412311134.1029.65
Total liabilities3,4022,8172,3351,8911,336947685
Assets
Gross block1,6051,4131,193828726552563
Net block1,044982776486428309303
Capital work in progress58.5827.119.429.872.5711.680.00
Investments0.000.7426.990.540.440.260.00
Inventories972846618485424404242
Sundry debtors645540453417395272243
Cash & bank balances99070467471534921293.73
Loans & advances11611490.8058.2232.2814.1114.66
Total current assets2,7232,2031,8361,6751,201903594
Total current liabilities454419336284287274207
Net working capital2,2691,7851,5001,391914628387
Total assets3,4022,8172,3351,8911,336947685
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash49640338220611293.7333.54
Net cash from operating activities45820723023799.26179233
Net cash from investing activities(249)(49.01)(141)(259)(84.39)(44.85)(59.58)
Net cash from financing activities(70.93)(65.15)(68.73)19879.51(15.29)(114)
Net change in cash13892.5120.8417694.3811860.19
Closing cash99070467471534921293.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%+13.4%
EBITDA growth+12.8%+16.2%+35.2%+31.1%-23.8%+76.7%+45.5%
PBT growth+11.2%+19.0%+25.4%+36.4%-18.1%+92.3%+50.7%
Net income growth+9.7%+21.1%+17.7%+44.4%-21.8%+95.4%+57.9%
Revenue CAGR (3Y)+16.8%+20.7%+16.5%+17.8%+14.2%+14.7%+13.9%
EBITDA CAGR (3Y)+21.0%+27.2%+10.5%+20.9%+25.1%+63.0%+62.6%
Profitability & leverage
Net income margin+14.2%+14.6%+14.5%+14.3%+12.5%+17.3%+10.7%
Return on capital employed+19.0%+20.2%+20.8%+21.8%+22.8%+38.8%+25.0%
Return on net worth+15.3%+16.9%+16.5%+18.0%+17.9%+31.3%+20.5%
Debt / equity0.120.120.100.080.070.040.11
Long-term debt / equity0.100.100.070.040.020.010.01
Interest cover4.812.602.913.183.952.635.28
Efficiency & per share
Fixed asset turnover1.962.012.152.382.332.472.12
Inventory turnover3.253.583.954.073.604.264.24
Debtors turnover4.985.285.014.564.475.345.40
EPS (₹)9.228.406.925.884.515.762.95
Dividend per share (₹)0.900.800.600.500.250.250.10
Book value per share (₹)66.7154.4445.5738.5127.1021.6615.54
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue321362340320320299312309
Revenue growth (YoY)+0.5%+20.8%+8.9%+3.8%+25.6%+32.9%+29.2%+50.8%
Other income17.4727.4815.8658.192.016.6422.5120.23
Total expenses239256264248250248252245
EBITDA82.1110675.4572.0770.0551.7659.9463.41
EBITDA margin+25.6%+29.3%+22.2%+22.5%+21.9%+17.3%+19.2%+20.5%
Depreciation8.788.768.838.468.198.187.427.02
Interest0.340.350.360.320.300.310.300.28
Profit before tax90.4612482.1212163.5749.9174.7376.34
Tax21.4232.4421.2121.6915.5212.3119.2613.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3411,174853655658600433
Revenue growth+5.3%+35.5%+26.6%+3.4%+12.1%+34.2%+0.3%
Other income10465.7962.0760.4842.2531.160.17
Total expenses1,018966713563545486362
Employee cost12210277.1956.0960.4654.6448.51
EBITDA32420814091.9011411471.50
EBITDA margin+24.1%+17.7%+16.4%+14.0%+17.3%+19.0%+16.5%
Depreciation34.2329.4529.1316.7417.6615.1911.64
Interest1.331.170.993.613.805.357.29
Profit before tax39224317213213412452.74
Tax90.8454.9838.1429.1730.5225.9514.83
Net profit29918713410310498.3737.88
Net profit margin+22.3%+16.0%+15.7%+15.7%+15.8%+16.4%+8.7%
EPS (₹)6.644.152.952.272.542.400.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3245.3245.3245.3240.9340.9340.93
Reserves & surplus1,6071,3381,1771,066651559465
Shareholders' funds (net worth)1,6521,3831,2231,111785600506
Secured loans0.000.000.000.000.000.000.05
Unsecured loans12.1310.848.137.6914.3114.3710.76
Total debt12.1310.848.137.6914.3114.3710.81
Total liabilities1,6701,4001,2351,122801621523
Assets
Gross block603555421319301277247
Net block398383272144136129115
Capital work in progress0.000.000.003.910.000.000.00
Investments267266293266237236236
Inventories18920519113110493.6974.60
Sundry debtors623550370305247169162
Cash & bank balances4472693124402241063.35
Loans & advances49.7358.0047.4636.5214.922.894.23
Total current assets1,3091,081921913589371244
Total current liabilities30734327121415611166.08
Net working capital1,002738649699434260178
Total assets1,6701,4001,2351,122801621523
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash60.2741.9314881.1982.423.351.80
Net cash from operating activities21131.0234.0551.7355.97107108
Net cash from investing activities(141)17.24(114)(195)(128)8.87(24.15)
Net cash from financing activities(39.23)(29.92)(26.22)21070.86(13.53)(81.87)
Net change in cash30.9818.34(106)67.12(1.23)1021.55
Closing cash4472693124402241063.35
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%+2.2%
EBITDA growth+55.5%+48.7%+52.3%-19.2%-0.0%+59.1%+12.9%
PBT growth+61.0%+41.5%+30.2%-1.8%+8.2%+135.8%-5.8%
Net income growth+59.6%+40.2%+29.9%-1.0%+5.7%+159.7%-13.2%
Revenue CAGR (3Y)+27.0%+21.3%+12.5%+14.8%+15.8%+26.7%+26.2%
EBITDA CAGR (3Y)+52.1%+22.3%+7.2%+8.7%+21.5%+57.5%+42.9%
Profitability & leverage
Net income margin+22.4%+16.0%+15.7%+15.7%+15.8%+16.4%+8.8%
Return on capital employed+25.6%+18.6%+14.7%+14.1%+19.5%+22.0%+10.2%
Return on net worth+19.8%+14.5%+11.5%+10.9%+15.0%+17.3%+7.1%
Debt / equity0.010.010.010.010.020.020.09
Long-term debt / equity0.010.010.010.000.010.010.01
Interest cover0.460.650.894.803.965.4312.18
Efficiency & per share
Fixed asset turnover2.322.412.312.112.282.291.84
Inventory turnover6.805.935.305.586.677.135.98
Debtors turnover2.292.552.532.373.173.622.55
EPS (₹)6.644.152.952.272.542.400.93
Dividend per share (₹)0.900.800.600.500.250.250.10
Book value per share (₹)36.4630.5326.9824.5216.9014.6512.35
Want more history and ratios?
You're viewing the latest exchange-filed financials for Marksans Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Marksans Pharma Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 43.90%, foreign institutional investors hold 17.50%, domestic institutional investors hold 6.20%, retail and other public shareholders hold 32.50% of Marksans Pharma Limited.

Promoters: 43.90%DII (Domestic Institutional): 6.20%FII (Foreign Institutional): 17.50%Retail & Others: 32.50%
Jun 2026
QUARTER
43.90% Promoters
6.20% DII (Domestic Institutional)
17.50% FII (Foreign Institutional)
32.50% Retail & Others
Promoter holding - history
Now 43.90% · Jun 2026High 43.90% · Sep 2025Low 43.90% · Sep 2025
42%42.8%43.5%44.3%45%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 43.90%Dec 2025: 43.90%Mar 2026: 43.90%Jun 2026: 43.90%43.90%43.90%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters43.90%43.90%43.90%43.90%
Public56.10%56.10%56.10%56.10%

Charges & Borrowings of Marksans Pharma Limited

Open charges
₹226 Cr
Satisfied charges
₹337.16 Cr
Breakdown by lending institutions
State Bank of India₹226.00 Cr
Latest charge details
DateLenderAmountStatus
07 Feb 2006 State Bank of India ₹226 Cr Open
07 Sep 2017 State Bank of India ₹66.8 Cr Satisfied
23 Jun 2015 State Bank of India ₹44.41 Cr Satisfied
23 Dec 2013 Bank of India ₹4 Cr Satisfied
13 Aug 2010 Bank of India ₹6 Cr Satisfied

Total charge records: 26 View all charges

Employees and EPFO Compliance at Marksans Pharma Limited

Marksans Pharma Limited has a workforce of 95 employees as of Apr 08, 2024.

Employee count
95
Active EPFO establishments
1
Employee growth
13.1%
Premium access

Employee and EPFO history for Marksans Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Marksans Pharma Limited

Premium access

GST registrations and filing compliance for Marksans Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Marksans Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Marksans Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Marksans Pharma Limited

Premium access

MSME payment history for Marksans Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Marksans Pharma Limited

Premium access

Corporate group structure for Marksans Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Marksans Pharma Limited

Premium access

MCA filings and documents for Marksans Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Marksans Pharma Limited

Activity
08 Aug 2025
Marksans Pharma Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records.
Directors
01 Apr 2025
Srinivas Mishra was appointed as a Director on 01 Apr 2025 & has been associated with this company since 1 year 5 months.
Activity
31 Mar 2025
Marksans Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
03 Feb 2025
A charge with State Bank Of India of Rs. 226.00 Cr registered on 07 Feb 2006 with Charge ID 80034914 was modified on 03 Feb 2025.
Directors
30 May 2023
Shailaja Vardhan was appointed as a Director on 30 May 2023 & has been associated with this company since 3 years 3 months.
Charges
29 Oct 2021
A charge registered on 07 Sep 2017 via Charge ID 100125187 with State Bank Of India was fully satisfied on 29 Oct 2021.

Recent News on Marksans Pharma Limited

Frequently Asked Questions about Marksans Pharma Limited

Marksans Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 16 April 1992 (34+ years old) and is registered under CIN L24110MH1992PLC066364. Listed on BSE: 524404 and NSE: MARKSANS. The company has 95 employees.

Marksans Pharma Limited reported revenue of ₹2,950.94 Cr for FY 2025-26 (up 12.51% YoY) based on consolidated financials.

The current directors of Marksans Pharma Limited are:

The primary industry of Marksans Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Marksans Pharma Limited is listed on both BSE (code: 524404) and NSE (symbol: MARKSANS).

Marksans Pharma Limited can be reached at the registered office: 11Th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri W, Mumbai, Maharashtra, India – 400053, or through the website marksanspharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available